Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Carboplatin + Etoposide ± Tiragolumab in Untreated Extensive-Stage Small Cell Lung Cancer
2022-502988-37-00Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Tecentriq + carboplatin + etoposide + tiragolumab with Tecentriq + carboplatin + etoposide + placebo (2 arms). Primary endpoints: Progression-free survival in the PAS and Overall survival in the PAS. Started Sep 2024; status: completed.
02
Drugs
atezolizumabtiragolumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2022-502988-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502988-37-00.